A recent study using methotrexate packaged in tumor-derived particles switched the macrophage phenotype from immunosuppressive M2 to proinflammatory M1 by activating lysosomal P450 monooxygenases and IFN-β production through hnRNPA2/B1 [172]. This evidence concerns the gene HNRNPA2B1 and neoplasm.